Challenge to clonal selection Over the past year or two Irun Cohen, from the Weizmann Institute in Israel, has been mounting a more radical attack on the clonal selection theory.4 He draws partly on older information, such as the well established fact that many proteins prove unable to induce an immune response without the help of an adjuvant. This alone is sufficient to dispose of the idea that engaging a receptor with antigen is all that is required. Attempts to explain adjuvants simply as devices for maintaining the right local concentration of antigen have failed. Another ofhis arguments is the restricted range of autoimmune diseases. Burnet thought that these diseases resulted from mutations in receptor-encoding genes, so that each case should be unique. In reality the number of such diseases is quite small, perhaps less than 30 in all, with many subjects suffering from each one. Perhaps the most telling argument comes from recent studies on autoreactive T cells in tissue culture. It has long been known that normal subjects contain occasional T cells able to react against self B cells and self macrophages, but it has not proved possible to identify just what antigens, if any, are involved. The position changed when well. defined proteins became available from studies on autoimmune diseases. All of the antigens identified as targets of autoimmunity so far tested prove able to stimulate T cells from normal subjects. The list of proteins that are 'noisy' in this way includes myelin basic protein, heat shock proteins, acetylcholine receptor, and thyroid peroxidase. It probably also includes type II collagen, though a question mark hangs over earlier data because of contamination with the porcine pepsin used to solubilise the collagen.5 Nobody knows why T cells of these types do not cause autoimmune disease in normal subjects. Some of these proteins may be too well hidden from cells of the immune system, but this seems unlikely to account for the whole phenomenon. It is tempting to believe that these T cells are held normally under some kind of restraint, from which they escape in culture. The figure attempts to summarise this position.
Arguments of this sort have conjured up a certain rhetoric. Cohen refers to 'committee decisions', and Janeway to 'costimulation'.6 Grossman prefers 'contextual discrimination',7 a useful term because it avoids reference to any particular mechanism. We have to accept the fact that the challenge to clonal selection theory comes from a diffuse range of possibilities rather than a single, coherent idea. The problem is not the lack of possible mechanisms, but rather the plethora. The context within which a lymphocyte makes its decision is set by the totality of receptors and adhesion molecules that it carries on its A cartoon ofthe T cell repertoire that combines Cohen's ideas with negative selection. HSP, MBP, AchR, TPO, and FLP are the noisy selfproteins mentioned in the text.
They prime T cells, which in turn are contained by constraining T cells. The repertoire also has holes, punched by negative selection in the thymus. The background repertoire hasfor the most part also been generated by postthymic positive selection, by environmental antigens.
surface, plus the cytokines and cell surface ligands to which it is exposed. Getting on for 100 proteins have been identified on the surface of human lymphocytes, so the choice is wide. Of course there are shades of opinion, often influenced by the personal experience of individual investigators. Some emphasise the importance of network interactions, others the cytokine cascade, and yet others the secondary signalling pathways served by particular adhesion-ligand pairs. There is no consensus, and insufficient data to base one on. The question is rather, what is the best experiment to do now?
Two pieces of my own experience draw me to this position. Guided by Hardy Cinader, then at the old Lister Institute, I had begun to study the antibody response of mice to foreign serum proteins such as albumin and immunoglobin. I confirmed Cinader's discovery that these proteins make excellent antigens when administered in adjuvant. My student David Dresser went on to discover that it was almost impossible to make a mouse respond to these soluble proteins without adjuvant, and that on the contrary they would become immunologically tolerant.8 Eventually, he found that the adjuvant did not even need to be mixed with the foreign protein in order to secure an antibody response but could be' injected elsewhere in the body. This disposed of the local concentration argument, and told us quite clearly that individual lymphocytes must respond to two signals, one from the antigen and the other from the adjuvant.
My second experience springs from the first. So where does all this leave clonal selection? Cohen writes about the breaking of a paradigm. When he does so I reach, mentally, for my toaster, as that is where as a schoolboy I learned that a boaster should be put. It takes a generation to feel fully at home with a new concept, and I believe that it has taken us that long to come to terms with clonal selection. Now that we are quite confident about the ability of negative selection to account for most of tolerance of self, we can start probing the edges where natural selection, the great tinkerer, no doubt has some surprises for us. One is reminded of the probing of the edges of mendelian inheritance which took place in the 1 940s. That too was separated from the rediscovery of Mendel's work by a generation, and was misinterpreted as a loss of confidence in mendelism.
Response to self proximal immunogens Most of the animal models of autoimmunity now in use can be traced back to the introduction of Freund's adjuvant in the 1940s, and the subsequent discovery of its ability to allow autoimmunisation with such tissues as spinal cord, peripheral nerve, uveal tract, and testis. Arthritis induced by type II collagen joined the list a little later. Other forms of insult could sometimes replace Freund's adjuvant, as in renal disease produced by in situ treatment of glomerular basement membrane with mercury ions. My point is that the older immunisation models (the purely genetical models are omitted from discussion as their underlying immunisation processes are so poorly understood) open only a fairly arbitrary window on self tolerance.
In trying to conceive how the window might be opened wider, I have been much influenced by the work of my colleague Susanne Schneider. She studies the response of mouse T cells to what is probably a single amino acid substituted variant of their own F liver protein. 9 The variant was chosen because it occurs naturally in certain mouse strains, and the system demonstrates alloimmunisation, leading to an exceptionally strong autoantibody response. So strong is this response that the protein, of unknown normal function, has long been recognised as immunologically 'noisy'. Susanne is discovering that it is also noisy as an autoantigen in the way mentioned above. Immunised mice contain CD4 T cells which respond in culture to self-type F liver protein, despite the fact that they make no detectable response to it in vivo. Because the protein has been cloned and sequenced she can now proceed with detailed epitope analysis. 
For this purpose she uses T cell hybridomas, a powerful technology for the mouse, which much needs transferring to man. This autoresponse to an alloprotein has obvious similarities to the well known autoimmunity that develops transiently in mice after immunisation with rat blood cells, but unfortunately that is not a system readily open to epitope analysis.
The need to search for other usable allovariations in protein structure has passed. These days one can obtain single amino acid substitutions at will by site specific mutagenesis, which could be used to generate self proximal antigens ad infinitum. This opens the way to a systematic probing of the borders of self tolerance.
In addition to this use in exploring the T cell repertoire, self proximal antigens should have valuable immunogenetic features. As simple epitopes, they are likely to show strong major histocompatibility complex (MHC) associations. Experience, admittedly with only a tiny number of these antigens, suggests that not only are positive associations likely to be found but also negative ones.'0 Such immunoinhibitory effects may well be analogous to the protection against rheumatoid arthritis displayed by HLA-DR4-Dw10 and DQ-Dw6. A deeper understanding of the mode of action of these protective genes is likely to lead to new therapeutic strategies: any mechanism which prevents a disease is likely also to help cure it.
Collagen induced arthritis and the minimax family This experimental disease is admirably suited for such an investigation. The 
